Flexible Flat-Rate Plans

Flat-rate pricing for predictable budgeting

Short-term plans for project- or client-based billing

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 8,426,586

« Back to Dashboard
Patent 8,426,586 protects GILOTRIF and is included in one NDA.

This patent has fifty-three patent family members in thirty countries.

Summary for Patent: 8,426,586

Title:Process for preparing amino crotonyl compounds
Abstract: An improved process for preparing 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(N,N-dimethylamino)-1-oxo-2-bute- n-1-yl]amino}-7-((S)-tetrahydrofuran-3-yloxy)-quinazoline and related aminocrotonyl compounds and the preparation of a suitable salt of 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(N,N-dimethylamino)-1-oxo-2-bute- n-1-yl]amino}-7-((S)-tetrahydrofuran-3-yloxy)-quinazoline for use as a pharmaceutically active substance.
Inventor(s): Soyka; Rainer (Biberach, DE), Rall; Werner (Mittelbiberach, DE), Schnaubelt; Juergen (Oberhoefen/Warthausen, DE), Sieger; Peter (Mittelbiberach, DE), Kulinna; Christian (Attenweiler, DE)
Assignee: Boehringer Ingelheim International GmbH (Ingelheim am Rhein, DE)
Application Number:11/457,622
Patent Claim Types:
see list of patent claims
Compound; Process;
Patent Metrics:
Source: PatentQuant.com
Field: Organic fine chemistry
Back Citations: 0th percentile
Forward Citations: 1st percentile

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Boehringer Ingelheim
afatinib dimaleate
TABLET;ORAL201292-001Jul 12, 2013RXNo8,426,586Oct 10, 2029Y
Boehringer Ingelheim
afatinib dimaleate
TABLET;ORAL201292-002Jul 12, 2013RXNo8,426,586Oct 10, 2029Y
Boehringer Ingelheim
afatinib dimaleate
TABLET;ORAL201292-003Jul 12, 2013RXYes8,426,586Oct 10, 2029Y
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 8,426,586

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Germany103 49 113Oct 17, 2003

International Patent Family for Patent: 8,426,586

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
New Zealand547154► subscribe
Israel216249► subscribe
Japan2007510624► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.